Juan Ruano

Dr. Juan Ruano

Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Andalusia, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
JLJosé López-Miranda
José López-Miranda
CMCarmen Marin
Carmen Marin
EREmilio Ros
Emilio Ros
RCR. De Caterina
R. De Caterina
Lina BadimonLina Badimon
Lina Badimon
NYN. Yiannakouris
N. Yiannakouris

1 November 2005 in JACC
Verified
Journal Article
Closed access
Juan RuanoJuan Ruano
Juan Ruano
JLJosé López-Miranda
José López-Miranda
FJFRANCISCO FUENTES JIMENEZ
FRANCISCO FUENTES JIMENEZ
Juan Antonio MorenoJuan Antonio Moreno
Juan Antonio Moreno
CBCecilia Bellido
Cecilia Bellido
CMCarmen Marin
Carmen Marin

2 October 2007 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
CMCarmen Marin
Carmen Marin
Juan RuanoJuan Ruano
Juan Ruano
PPPABLO PEREZ-MARTINEZ
PABLO PEREZ-MARTINEZ
FLFernando Lopez‐Segura
Fernando Lopez‐Segura
JLJosé López-Miranda
José López-Miranda

20 April 2010 in BMC Genomics
Verified
Journal Article
Open access
PDF file
ACAntonio Camargo
Antonio Camargo
Juan RuanoJuan Ruano
Juan Ruano
JFJuan M Fernandez
Juan M Fernandez
LPLauence Parnell
Lauence Parnell
AJAnabel Jimenez
Anabel Jimenez
CMCarmen Marin
Carmen Marin
Background: Previous studies have shown that acute intake of high-phenol virgin olive oil reduces pro-inflammatory, pro-oxidant and pro-thrombotic markers compared with low phenols virgin olive oil, but it still remains unclear whether effects attributed to its phenolic fraction are exerted at transcriptional level in vivo. To achieve this goal, we aimed at identifying expression changes in genes which could be mediated by virgin olive oil phenol compounds in the human. Results: Postprandial gene expression microarray analysis was performed on peripheral blood mononuclear cells during postprandial period. Two virgin olive oil-based breakfasts with high (398 ppm) and low (70 ppm) content of phenolic compounds were administered to 20 patients suffering from metabolic syndrome following a double-blinded, randomized, crossover design. To eliminate the potential effect that might exist in their usual dietary habits, all subjects followed a similar low-fat, carbohydrate rich diet during the study period. Microarray analysis identified 98 differentially expressed genes (79 underexpressed and 19 overexpressed) when comparing the intake of phenol-rich olive oil with low-phenol olive oil. Many of these genes seem linked to obesity, dyslipemia and type 2 diabetes mellitus. Among these, several genes seem involved in inflammatory processes mediated by transcription factor NF-κB, activator protein-1 transcription factor complex AP-1, cytokines, mitogen-activated protein kinases MAPKs or arachidonic acid pathways. Conclusion: This study shows that intake of virgin olive oil based breakfast, which is rich in phenol compounds is able to repress in vivo expression of several pro-inflammatory genes, thereby switching activity of peripheral blood mononuclear cells to a less deleterious inflammatory profile. These results provide at least a partial molecular basis for reduced risk of cardiovascular disease observed in Mediterranean countries, where virgin olive oil represents a main source of dietary fat. Admittedly, other lifestyle factors are also likely to contribute to lowered risk of cardiovascular disease in this region.

1 June 2009 in Atherosclerosis
Verified
Journal Article
Closed access
YJYolanda Jimenez-Gomez
Yolanda Jimenez-Gomez
JLJosé López-Miranda
José López-Miranda
L.M. Blanco-ColioL.M. Blanco-Colio
L.M. Blanco-Colio
CMCarmen Marín
Carmen Marín
PPPABLO PEREZ-MARTINEZ
PABLO PEREZ-MARTINEZ
CMCarmen Marin
Carmen Marin

3 May 2016 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
JGJesus Gay-Mimbrera
Jesus Gay-Mimbrera
MGMaria Carmen García
Maria Carmen García
BIBeatriz Isla-Tejera
Beatriz Isla-Tejera
Antonio Rodero SerranoAntonio Rodero Serrano
Antonio Rodero Serrano
AGAntonio Vélez García-Nieto
Antonio Vélez García-Nieto
Juan RuanoJuan Ruano
Juan Ruano
Plasma-based electrosurgical devices have long been employed for tissue coagulation, cutting, desiccation, and cauterizing. Despite their clinical benefits, these technologies involve tissue heating and their effects are primarily heat-mediated. Recently, there have been significant developments in cold atmospheric pressure plasma (CAP) science and engineering. New sources of CAP with well-controlled temperatures below 40 °C have been designed, permitting safe plasma application on animal and human bodies. In the last decade, a new innovative field, often referred to as plasma medicine, which combines plasma physics, life science, and clinical medicine has emerged. This field aims to exploit effects of mild plasma by controlling the interactions between plasma components (and other secondary species that can be formed from these components) with specific structural elements and functionalities of living cells. Recent studies showed that CAP can exert beneficial effects when applied selectively in certain pathologies with minimal toxicity to normal tissues. The rapid increase in new investigations and development of various devices for CAP application suggest early adoption of cold plasma as a new tool in the biomedical field. This review explores the latest major achievements in the field, focusing on the biological effects, mechanisms of action, and clinical evidence of CAP applications in areas such as skin disinfection, tissue regeneration, chronic wounds, and cancer treatment. This information may serve as a foundation for the design of future clinical trials to assess the efficacy and safety of CAP as an adjuvant therapy for skin cancer.